How Amneal Pharmaceuticals Stock Has Been Trading Recently

Amneal Pharmaceuticals (AMRX) has been on many investors' radars after a period of mixed share performance, with the stock down over the past week, month, and past 3 months despite a strong 1 year total return.

Recent trading has been choppy, with the share price down over the past week and quarter, yet the 1 year and multi year total shareholder returns remain strong. This suggests earlier optimism is now being reassessed at the current US$12.39 level.

If you are comparing Amneal with other potential opportunities in the sector, it can be useful to see which healthcare stocks are using AI in meaningful ways through the 33 healthcare AI stocks.

With Amneal trading at US$12.39, at an implied discount to both analyst targets and some intrinsic value estimates, and with solid recent revenue and net income figures, the real question is whether this is a genuine opportunity or if the market has already priced in future growth.

Most Popular Narrative: 27.1% Undervalued

With Amneal closing at $12.39 against a narrative fair value of $17.00, the current setup depends on how the business mix shifts over the next few years.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Want to see what is sitting behind that growth story? The narrative focuses on the potential for higher margins, larger earnings and a reset future earnings multiple.

Result: Fair Value of $17.00 (UNDERVALUED)

However, this story can quickly change if pricing pressure in U.S. generics persists or if high debt limits Amneal’s ability to fund its planned pivots.

Another Way To Look At Amneal’s Valuation

The narrative fair value of $17.00 suggests upside, but the current P/E of 32.4x tells a more cautious story. It is higher than the US Pharmaceuticals industry at 15.6x and also above the 26.9x fair ratio the market could move towards, which raises the question of how much optimism is already in the price.

To see how that premium multiple compares with peers and the fair ratio in more detail, take a closer look at our valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of concern and optimism around Amneal feels familiar, do not sit on the sidelines. Weigh both sides and see how the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not let your research stop with one stock. The right tools can help you quickly spot fresh opportunities that match your goals and risk comfort.

• Target potential upside in quality companies that look attractively priced by scanning the 46 high quality undervalued stocks.
• Prioritize resilience and sleep-better-at-night holdings by reviewing the 68 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with strong fundamentals by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.